EuBiologics Co Ltd
KOSDAQ:206650
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8 900
17 210
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
EuBiologics Co Ltd
Gross Profit
EuBiologics Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
EuBiologics Co Ltd
KOSDAQ:206650
|
Gross Profit
₩48.2B
|
CAGR 3-Years
42%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Gross Profit
₩1.2T
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Gross Profit
₩142.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Gross Profit
₩278.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Gross Profit
₩211B
|
CAGR 3-Years
31%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Gross Profit
₩32.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
EuBiologics Co Ltd
Glance View
EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.
See Also
What is EuBiologics Co Ltd's Gross Profit?
Gross Profit
48.2B
KRW
Based on the financial report for Sep 30, 2024, EuBiologics Co Ltd's Gross Profit amounts to 48.2B KRW.
What is EuBiologics Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
21%
Over the last year, the Gross Profit growth was 90%. The average annual Gross Profit growth rates for EuBiologics Co Ltd have been 42% over the past three years , 21% over the past five years .
You don't have any saved screeners yet
